Bionano Genomics Management
Management criteria checks 3/4
Bionano Genomics' CEO is Robert Holmlin, appointed in Jan 2011, has a tenure of 14.42 years. total yearly compensation is $989.68K, comprised of 60.6% salary and 39.4% bonuses, including company stock and options. directly owns 0.027% of the company’s shares, worth $2.98K. The average tenure of the management team and the board of directors is 4.1 years and 6.1 years respectively.
Key information
Robert Holmlin
Chief executive officer
US$989.7k
Total compensation
CEO salary percentage | 60.63% |
CEO tenure | 14.4yrs |
CEO ownership | 0.03% |
Management average tenure | 4.1yrs |
Board average tenure | 6.1yrs |
Recent management updates
Recent updates
VIA Software And Optical Genome Mapping Will Improve Laboratory Efficiency
Enhancements in customer utilization and lab efficiency are projected to boost consumable sales and revenue growth.Revenues Working Against Bionano Genomics, Inc.'s (NASDAQ:BNGO) Share Price Following 26% Dive
Apr 05Slammed 62% Bionano Genomics, Inc. (NASDAQ:BNGO) Screens Well Here But There Might Be A Catch
Feb 11Bionano Genomics, Inc. (NASDAQ:BNGO) Might Not Be As Mispriced As It Looks
Dec 17Many Still Looking Away From Bionano Genomics, Inc. (NASDAQ:BNGO)
Aug 29CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Mar 31 2025 | n/a | n/a | -US$84m |
Dec 31 2024 | US$990k | US$600k | -US$112m |
Sep 30 2024 | n/a | n/a | -US$136m |
Jun 30 2024 | n/a | n/a | -US$204m |
Mar 31 2024 | n/a | n/a | -US$227m |
Dec 31 2023 | US$1m | US$599k | -US$232m |
Sep 30 2023 | n/a | n/a | -US$227m |
Jun 30 2023 | n/a | n/a | -US$147m |
Mar 31 2023 | n/a | n/a | -US$140m |
Dec 31 2022 | US$3m | US$544k | -US$133m |
Sep 30 2022 | n/a | n/a | -US$117m |
Jun 30 2022 | n/a | n/a | -US$106m |
Mar 31 2022 | n/a | n/a | -US$92m |
Dec 31 2021 | US$8m | US$484k | -US$72m |
Sep 30 2021 | n/a | n/a | -US$61m |
Jun 30 2021 | n/a | n/a | -US$51m |
Mar 31 2021 | n/a | n/a | -US$41m |
Dec 31 2020 | US$708k | US$376k | -US$41m |
Sep 30 2020 | n/a | n/a | -US$37m |
Jun 30 2020 | n/a | n/a | -US$33m |
Mar 31 2020 | n/a | n/a | -US$32m |
Dec 31 2019 | US$899k | US$404k | -US$30m |
Sep 30 2019 | n/a | n/a | -US$28m |
Jun 30 2019 | n/a | n/a | -US$27m |
Mar 31 2019 | n/a | n/a | -US$23m |
Dec 31 2018 | US$3m | US$390k | -US$18m |
Compensation vs Market: Robert's total compensation ($USD989.68K) is above average for companies of similar size in the US market ($USD647.94K).
Compensation vs Earnings: Robert's compensation has been consistent with company performance over the past year.
CEO
Robert Holmlin (57 yo)
Dr. Robert Erik Holmlin, Ph D., M.B.A. has been the Chief Executive Officer and President of BioNano Genomics, Inc. (alternatively BioNanomatrix, Inc.) since January 12, 2011 and served as its Secretary &...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 14.4yrs | US$989.68k | 0.027% $ 3.0k | |
Chief Operating Officer | 7.6yrs | US$663.37k | 0.016% $ 1.7k | |
Chief Medical Officer | 4.8yrs | US$661.91k | 0.0068% $ 752.3 | |
VP of Accounting & Controller | 7yrs | no data | 0.0033% $ 369.5 | |
General Counsel & Secretary | 3.3yrs | no data | 0.0033% $ 369.5 | |
Vice President of Global Sales | 3.4yrs | no data | no data | |
Global Head of Market Access | 2.6yrs | no data | no data | |
Global Head of People Operations | 3.4yrs | no data | no data |
Experienced Management: BNGO's management team is considered experienced (4.1 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 14.4yrs | US$989.68k | 0.027% $ 3.0k | |
Independent Director | 6.9yrs | US$76.86k | 0.0036% $ 395.0 | |
Independent Director | 15.1yrs | US$91.09k | 0.0032% $ 358.4 | |
Independent Chairman | 13.7yrs | US$87.62k | 0% $ 0 | |
Independent Director | 5.1yrs | US$64.36k | 0.0036% $ 401.7 | |
Independent Director | 6.1yrs | US$74.36k | 0% $ 0 | |
Independent Director | 5.1yrs | US$61.86k | 0% $ 0 | |
Independent Director | 3.5yrs | US$66.86k | 0% $ 0 | |
Independent Director | 3.3yrs | US$61.86k | 0% $ 0 |
Experienced Board: BNGO's board of directors are considered experienced (6.1 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/06/04 12:56 |
End of Day Share Price | 2025/06/04 00:00 |
Earnings | 2025/03/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bionano Genomics, Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Mark Massaro | BTIG |
Yi Chen | H.C. Wainwright & Co. |
Jason McCarthy | Maxim Group |